BR0314548A - Terapias para polineuropatia de desmielinação inflamatória crÈnica empregando-se interferon-beta - Google Patents

Terapias para polineuropatia de desmielinação inflamatória crÈnica empregando-se interferon-beta

Info

Publication number
BR0314548A
BR0314548A BR0314548-4A BR0314548A BR0314548A BR 0314548 A BR0314548 A BR 0314548A BR 0314548 A BR0314548 A BR 0314548A BR 0314548 A BR0314548 A BR 0314548A
Authority
BR
Brazil
Prior art keywords
interferon
therapies
beta
chronic inflammatory
inflammatory demyelination
Prior art date
Application number
BR0314548-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Alfred Sandrock
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of BR0314548A publication Critical patent/BR0314548A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/215IFN-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BR0314548-4A 2002-09-27 2003-09-26 Terapias para polineuropatia de desmielinação inflamatória crÈnica empregando-se interferon-beta BR0314548A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41430702P 2002-09-27 2002-09-27
PCT/US2003/030532 WO2004028472A2 (en) 2002-09-27 2003-09-26 THERAPIES FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY USING INTERFERON-β

Publications (1)

Publication Number Publication Date
BR0314548A true BR0314548A (pt) 2005-08-09

Family

ID=32043377

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314548-4A BR0314548A (pt) 2002-09-27 2003-09-26 Terapias para polineuropatia de desmielinação inflamatória crÈnica empregando-se interferon-beta

Country Status (21)

Country Link
US (2) US20060182715A1 (enExample)
EP (1) EP1575531B9 (enExample)
JP (3) JP2006513990A (enExample)
KR (1) KR20050059195A (enExample)
CN (2) CN102038938A (enExample)
AT (1) ATE520412T1 (enExample)
AU (1) AU2003277006C1 (enExample)
BR (1) BR0314548A (enExample)
CA (1) CA2500189A1 (enExample)
DK (1) DK1575531T3 (enExample)
EA (1) EA009289B1 (enExample)
GE (1) GEP20094699B (enExample)
IS (1) IS7746A (enExample)
MX (1) MXPA05003243A (enExample)
NO (1) NO20052059L (enExample)
NZ (1) NZ565990A (enExample)
PL (1) PL377612A1 (enExample)
RS (1) RS20050255A (enExample)
UA (1) UA86749C2 (enExample)
WO (1) WO2004028472A2 (enExample)
ZA (1) ZA200502416B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1575531T3 (da) * 2002-09-27 2011-11-21 Biogen Idec Inc Terapier for kronisk inflammatorisk demyeliniserende polyneuropati under anvendelse af interferon-beta
TW200633718A (en) * 2004-12-16 2006-10-01 Applied Research Systems Treatment of hepatitis c in the asian population
EP2572734B1 (en) * 2006-10-31 2016-04-06 East Carolina University Cytokine-based fusion proteins for treatment of immune disorders
EP3348275A3 (en) 2009-03-31 2018-10-24 East Carolina University Cytokines and neuroantigens for treatment of immune disorders
CA2850469C (en) * 2011-10-01 2020-07-07 Glytech, Inc. Glycosylated polypeptide and pharmaceutical composition containing same
GB201212878D0 (en) 2012-07-20 2012-09-05 Pike Justin Authentication method and system
EP3072513A1 (en) 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis
GB201520760D0 (en) 2015-05-27 2016-01-06 Mypinpad Ltd And Licentia Group Ltd Encoding methods and systems
WO2020009437A1 (ko) * 2018-07-04 2020-01-09 서울대학교산학협력단 신경손상의 면역세포치료
GB201916441D0 (en) 2019-11-12 2019-12-25 Mypinpad Ltd Computer-implemented system and method

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0154316B1 (en) * 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
ZA878295B (en) * 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease
DE3712564A1 (de) * 1987-04-14 1988-11-24 Bioferon Biochem Substanz Verfahren zur konstruktion einer animalen zellinie fuer die herstellung von humanem interferon-beta
DE4128319A1 (de) * 1991-08-27 1993-03-04 Bioferon Biochem Substanz Neues rekombinantes human-ifn-beta, verfahren zu dessen herstellung und dieses enthaltende pharmazeutische zubereitungen
US5545723A (en) * 1994-03-15 1996-08-13 Biogen Inc. Muteins of IFN-β
ZA952797B (en) * 1994-04-12 1996-10-07 Res Dev Foundation Method of treating auto-immune diseases using type one interferons
IL113280A (en) * 1994-04-12 2004-12-15 Res Dev Foundation A preparation for the treatment of self-immunization diseases with the help of interferon of one type
TW403653B (en) * 1995-12-25 2000-09-01 Otsuka Pharma Co Ltd Dry compositions
ES2265693T3 (es) * 1998-10-16 2007-02-16 Biogen Idec Ma Inc. Proteinas de fusion con interferon-beta y usos.
AU762616B2 (en) * 1998-10-16 2003-07-03 Biogen Ma Inc. Polymer conjugates of interferon beta-1a and uses
US6419934B1 (en) * 1999-02-24 2002-07-16 Edward L. Tobinick TNF modulators for treating neurological disorders associated with viral infection
JP2002537769A (ja) * 1999-02-26 2002-11-12 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド ヒトエンドカインαおよび使用方法
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
EP1334128A2 (en) * 2000-11-02 2003-08-13 Maxygen Aps New multimeric interferon beta polypeptides
JP2004534523A (ja) * 2001-02-27 2004-11-18 マキシゲン・エイピーエス 新規なインターフェロンβ様分子
WO2002072019A2 (en) * 2001-03-13 2002-09-19 Vical Incorporated Interferon-beta polynucleotide therapy for autoimmune and inflammatory diseases
DK1575531T3 (da) * 2002-09-27 2011-11-21 Biogen Idec Inc Terapier for kronisk inflammatorisk demyeliniserende polyneuropati under anvendelse af interferon-beta

Also Published As

Publication number Publication date
EP1575531A4 (en) 2008-01-23
GEP20094699B (en) 2009-06-10
ATE520412T1 (de) 2011-09-15
NO20052059D0 (no) 2005-04-27
CA2500189A1 (en) 2004-04-08
IS7746A (is) 2005-03-15
MXPA05003243A (es) 2005-09-12
WO2004028472A3 (en) 2006-01-19
KR20050059195A (ko) 2005-06-17
PL377612A1 (pl) 2006-02-06
EP1575531A2 (en) 2005-09-21
RS20050255A (sr) 2007-08-03
JP2007039463A (ja) 2007-02-15
JP2006513990A (ja) 2006-04-27
CN102038938A (zh) 2011-05-04
US20120058083A1 (en) 2012-03-08
AU2003277006A1 (en) 2004-04-19
AU2003277006C1 (en) 2010-04-01
UA86749C2 (en) 2009-05-25
EA009289B1 (ru) 2007-12-28
JP2011132248A (ja) 2011-07-07
WO2004028472A2 (en) 2004-04-08
CN1802170A (zh) 2006-07-12
US20060182715A1 (en) 2006-08-17
DK1575531T3 (da) 2011-11-21
EP1575531B1 (en) 2011-08-17
AU2003277006B2 (en) 2009-09-10
EA200500545A3 (ru) 2007-04-27
NO20052059L (no) 2005-06-27
NZ565990A (en) 2009-10-30
EP1575531B9 (en) 2012-02-22
EA200500545A2 (ru) 2005-08-25
ZA200502416B (en) 2005-10-20

Similar Documents

Publication Publication Date Title
WO2004006756A3 (en) THERAPIES FOR RENAL FAILURE USING INTERFERON-β
DK1539166T3 (da) Farmaceutiske sammensætninger indeholdende dextromethorphan og quinidin til behandling af neurologiske sygdomme
BRPI0414435A (pt) métodos e reagentes para o tratamento de distúrbios imunoinflamatórios
DE60206028D1 (de) Oxazolylpyrazol-derivate als kinase-inhibitoren
BRPI0912411A2 (pt) uso de uma muteína de interleucina humana-2 (muteína de hil-2) ou de um fragmento da mesma, composição farmacêutica para o tratamento e/ou profilaxia de uma doença autoimune, uso de muteína de interleucina humana-2 (muteína de hil-2) ou de uma seção da mesma, agete para formação de células t regulatórias (treg) em um organismo, método para tratamento e/ou profilaxia de uma doença autoimune em um organismo, método para formação de células t regulatórias (treg) em um organismo, método para formação de células t regulatórias (treg) in vitro.
BRPI0413974A (pt) combinação, método de tratamento de cáncer em um animal de sangue quente, composição farmacêutica, e, uso de uma combinação
MXPA04006572A (es) Terapia de combinacion antivirica.
ATE369355T1 (de) Pyrimidinamid derivate und deren verwendung
BR0314548A (pt) Terapias para polineuropatia de desmielinação inflamatória crÈnica empregando-se interferon-beta
CY1110162T1 (el) Φαρμακοτεχνικη μορφη και μεθοδοι για την αγωγη της θρομβοκυτταραιμιας
CY1110712T1 (el) Χρηση ν-(3-μεθοξυ-5-μεθυλπυραζιν-2-υλ)-2-(4-[1,3,4-οξαδιαζολ-2-υλ]φαινυλ)πυριδινο-3-σουλφοναμιδης στη θεραπευτικη αντιμετωπιση του καρκινου
MA55799A (fr) Polythérapies comprenant de l'aprémilast et des inhibiteurs de tyk2
EA200602047A1 (ru) Сульфонилэтилфосфородиамидаты, предназначенные для применения при лечении рака
BRPI0416882A (pt) composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
CY1107312T1 (el) Θειικη 3,5,3’-τριιωδοθυρονινη σαν θυρεοειδο-μιμητικος παραγοντας και φαρμακευτικα σκευασματα της
NO20034561L (no) Anvendelse av kationiske dekstranderivater for beskyttelse av dosebegrensende organer
HRP20080597T3 (en) Cancer combination therapy comprising azd2171 and zd1839
DE60321175D1 (de) Dichloracetat in kombination mit kardioprotektiven oder hämodynamischen medikamenten
EP1364652A4 (en) DRUGS FOR LUNG CANCER
BR112022007632A2 (pt) Composição farmacêutica e preparação de kit para tratamento de câncer, e, métodos para tratamento de câncer e de um paciente com câncer
CY1105117T1 (el) Θepαπειες για τη χρονια νεφρικη ανεπαρκεια χρησιμοποιωντας ανταγωνιστες των ενσωματινων
DK1708693T3 (da) Farmaceutiske sammensætninger indeholdende platinkomplekser med sekundære xanthater og terapeutiske anvendelser deraf
MA55781A (fr) Polythérapies comprenant de l'aprémilast et des inhibiteurs de tyk2
MXPA05002477A (es) Asialo-interferones y el tratamiento de cancer de higado.
TW200510447A (en) Novel fusidic acid derivatives

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.